MA39888A - Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1 - Google Patents

Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1

Info

Publication number
MA39888A
MA39888A MA039888A MA39888A MA39888A MA 39888 A MA39888 A MA 39888A MA 039888 A MA039888 A MA 039888A MA 39888 A MA39888 A MA 39888A MA 39888 A MA39888 A MA 39888A
Authority
MA
Morocco
Prior art keywords
tetrahydropyrrolo
pyrazolo
pyrazole
tetrahydro
substituted
Prior art date
Application number
MA039888A
Other languages
English (en)
Inventor
Jillian Basinger
Brett Bookser
Mi Chen
Demichael Chung
Varsha Gupta
Andrew Hudson
Alan Kaplan
James Na
Joel Renick
Vincent Santora
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of MA39888A publication Critical patent/MA39888A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne une entité chimique de formule (i), dans laquelle r
MA039888A 2014-04-24 2015-04-22 Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1 MA39888A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983821P 2014-04-24 2014-04-24

Publications (1)

Publication Number Publication Date
MA39888A true MA39888A (fr) 2017-03-01

Family

ID=53373533

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039888A MA39888A (fr) 2014-04-24 2015-04-22 Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1

Country Status (5)

Country Link
US (1) US9708334B2 (fr)
EP (1) EP3134406A1 (fr)
MA (1) MA39888A (fr)
TW (1) TW201625608A (fr)
WO (1) WO2015164520A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040759B2 (en) 2014-11-05 2018-08-07 Dart Neuroscience (Cayman) Ltd. Substituted azetidinyl compounds as GlyT1 inhibitors
US10383335B2 (en) 2015-04-09 2019-08-20 Fmc Corporation Bicyclic pyrazole pesticides
CN110551123A (zh) * 2019-07-23 2019-12-10 常州合全药业有限公司 一种5-(叔丁氧羰基)-2-甲基-4,5,6,7-四氢-2h-吡唑并[4,3-c]吡啶-7-羧酸的制备方法
IL294674A (en) * 2020-01-13 2022-09-01 Aptabio Therapeutics Inc Pirzol derivative

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
EP2316531A1 (fr) 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Apprentissage cognitif amélioré
ATE305917T1 (de) 2001-08-16 2005-10-15 Pfizer Prod Inc Difluormethylen aromatische ether und ihre verwendung als inhibitoren des glycin-typ-1- transporters
MXPA05000945A (es) * 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
PE20040804A1 (es) * 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
JP4252598B2 (ja) 2003-08-11 2009-04-08 エフ．ホフマン−ラ ロシュ アーゲー Ｏｒ置換フェニル基を有するピペラジン及びｇｌｙｔ１阻害剤としてのこれらの使用
BRPI0414209B8 (pt) 2003-09-09 2021-05-25 Hoffmann La Roche derivados de 1-(2-amino-benzol)-piperazina, seus processos de preparação e seu uso, e medicamento
BRPI0413536B8 (pt) 2003-09-09 2021-05-25 Hoffmann La Roche derivados de 1-benzoil-piperazina, seu uso e medicamento que os compreende
KR100798161B1 (ko) 2003-10-23 2008-01-28 에프. 호프만-라 로슈 아게 신경병적 또는 신경정신병적 장애의 치료에서 ｇｌｙｔ-1저해제로서 사용하기 위한 트라이아자-스피로피페리딘유도체
US20070105902A1 (en) 2003-11-12 2007-05-10 Lindsley Craig W 4-Phenyl piperdine sulfonyl glycine transporter inhibitors
EP1797035B1 (fr) 2004-09-30 2010-11-17 Merck Sharp & Dohme Corp. Inhibiteurs du transporteur de la glycine de piperidine de cyclopropyle
DE602005022113D1 (de) * 2005-01-07 2010-08-12 Hoffmann La Roche Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
GB0505086D0 (en) 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
CN101189228A (zh) 2005-04-08 2008-05-28 辉瑞产品有限公司 用作i型甘氨酸转运抑制剂的二环[3.1.0]杂芳酰胺
JP5281395B2 (ja) 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のｇｌｙｔ１阻害剤としてのシクロヘキサンスルホニル誘導体
RU2437872C2 (ru) 2006-06-22 2011-12-27 Ф. Хоффманн-Ля Рош Аг Замещенные производные фенилметанона
SI2041088T1 (sl) 2006-06-28 2014-05-30 Amgen Inc. Inhibitorji transporter-1 glicina
ES2392105T3 (es) 2006-08-30 2012-12-04 F. Hoffmann-La Roche Ag Inhibidores de GlyT-1
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
AU2008254907A1 (en) 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of identifying genes involved in memory formation using small interfering RNA(siRNA)
GB0813694D0 (en) 2008-07-25 2008-09-03 Glaxo Group Ltd Compounds
HUE028378T2 (hu) * 2011-09-16 2016-12-28 Sanofi Sa Helyettesített 4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridinek, gyógyszerként való alkalmazásuk, és az ezeket tartalmazó gyógyászati készítmények
WO2013037914A1 (fr) * 2011-09-16 2013-03-21 Sanofi 4,5,6,7-tétrahydro-1h-pyrazolo[4,3-c]pyridines substituées, leur utilisation comme médicament, et préparations pharmaceutiques les contenant

Also Published As

Publication number Publication date
WO2015164520A1 (fr) 2015-10-29
US9708334B2 (en) 2017-07-18
TW201625608A (zh) 2016-07-16
EP3134406A1 (fr) 2017-03-01
US20170044167A1 (en) 2017-02-16
WO2015164520A4 (fr) 2015-12-17

Similar Documents

Publication Publication Date Title
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
HK1248695A1 (zh) 用作cbp和/或ep300抑制劑的4，5，6，7-四氫-1h-吡唑並[4，3-c]吡啶-3-胺化合物
PH12017501340A1 (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
IL265916B (en) Converted pyrazolo[1,5–a]pyridine compounds as ret kinase inhibitors
IL256898B (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
SG10201807952PA (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
ZA201808257B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
EP3319966A4 (fr) Composés hétérocycliques bicycliques utilisés comme inhibiteurs de pde2
MA39888A (fr) Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1
HK1248686A1 (zh) 適用於治療癌症的1-(環)烷基吡啶-2-酮的三環稠合衍生物
TW201612165A (en) Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound
AU2015311730A8 (en) CaMKII inhibitors and uses thereof
EP3368516A4 (fr) Composés pyrazoles bicycliques substitués en tant qu'inhibiteurs de rorgammat et leurs utilisations
EP3285581A4 (fr) Composés pyrazolyle pyrimidinone utilisés en tant qu'inhibiteurs de pde2